Tumor Angiogenesis Promoted by Ex vivo Differentiated Endothelial Progenitor Cells Is Effectively Inhibited by an Angiogenesis Inhibitor, TK1-2

Abstract

Neovascularization plays a critical role in the growth and metastatic spread of tumors and involves recruitment of circulating endothelial progenitor cells

Endothelial progenitor cells for cancer gene therapy

“…Further research is needed to determine how to prolong protection of EPCs, such as, by transfer of genes encoding antiapoptotic molecules, without jeopardizing the elimination of EPCs at the end of therapy. Terminal elimination is required to prevent the proangiogenic effects of surviving EPCs leading to increased growth of remaining tumor tissue 78 and to preclude the remote possibility of malignant transformation of the highly proliferative EPCs.…”

Ginsenoside Rg3 attenuates tumor angiogenesis via inhibiting bioactivities of endothelial progenitor cells

“…10,11 Therefore, the specific targeting of EPC bioactivities appears to be one of potent targets for antiangiogenic therapy without side effects. [7][8][9]34 The present data showed that the major biologically active component of the natural medicine of ginseng, Ginsenoside Rg3, attenuates tumor growth and neovessel formation by targeting functional activities of the resident EPCs. Based on these results, it was concluded that Ginsenoside Since Ginsenoside Rg3 can affect the functional tubular formation capability of EPCs, the tube forming assay was next performed after the activation of EPCs with increasing concentrations of Ginsenoside Rg3.…”

Cells as vehicles for therapeutic genes to treat liver diseases

“…This property makes EPCs useful tools to convey therapeutic genes to diseased organs in patients with tissue damage or neoplastic conditions. 57 However, the number of EPC that can be obtained for clinical use is scarce and may be insufficient for specific applications. Moreover, in some circumstances such as diabetes or obesity EPCs may be dysfunctional.…”